Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.45 |
| ▸ | CDK9 | P50750 | 3/20 | 0.45 |
| ▸ | CIT | O14578 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009838 | 0.87 | JAK1 (0.67) | JAK1CCNT1CDK9 | |
| SCHEMBL30009362 | 0.82 | JAK1 (0.63) | JAK1CCNT1CDK9PIK3C3 | |
| SCHEMBL20917940 | 0.80 | JAK1 (0.84) | JAK1 | |
| SCHEMBL30355974 | 0.80 | JAK1 (0.84) | JAK1 | |
| SCHEMBL30009346 | 0.79 | JAK1 (0.65) | JAK1CCNT1CDK9PIK3C3 | |
| SCHEMBL30009242 | 0.74 | JAK1 (0.58) | JAK1CCNT1CDK9PIK3C3 | |
| SCHEMBL30009522 | 0.74 | JAK1 (0.50) | JAK1CCNT1CDK9CITPIK3C3 | |
| SCHEMBL20917856 | 0.70 | JAK1 (1.00) | JAK1 | |
| SCHEMBL30356133 | 0.70 | JAK1 (1.00) | JAK1 | |
| SCHEMBL20919134 | 0.69 | JAK1 (1.00) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885CCNT1 2852/4885CDK9 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.